James Nealon

ARTMS Inc

ARTMS Inc. is the global leader in the development of novel technologies and products for enabling the cyclotron production of the world's most-used diagnostic imaging isotopes, including gallium-68 (68Ga), technetium‐99m (99mTc), zirconium-89 (89Zr) and copper-64 (64Cu). ARTMS' novel solid targetry approach allows for the production of the highest activity and highest quality of clinically valuable medical isotopes available. ARTMS also partners with biotechnology and radiopharmaceutical companies to concurrently develop specific GMP medical isotopes alongside their radiopharmaceuticals during all phases of preclinical and clinical development and commercialization. In 2019, ARTMS submitted its first marketing authorization application for cyclotron produced Tc-99m. ARTMS will follow similar regulatory approaches for its next suite of products.